key: cord-1045559-auzankq2
authors: Salzer, Helmut J. F.
title: Emerging COVID-19 reinfection four months after primary SARS-CoV-2 infection
date: 2021-02-08
journal: Wien Med Wochenschr
DOI: 10.1007/s10354-021-00813-1
sha: e5671b54b0c72532df27822e26b22b5ff3261750
doc_id: 1045559
cord_uid: auzankq2

nan

of 89% on room air and an elevated body temperature of 38.4°C. Auscultation of the lung revealed no pathological abnormalities, while laboratory test results showed mild leukopenia with 3.18 G/L (reference value 3.9-8.8 G/L) with a decreased lymphocyte count of 0.64 G/L (reference value 1.00-4.00 G/L) and a thrombocytopenia with 126 G/L (reference value 151-400 G/L), respectively. Other laboratory values and urine test results were unremarkable. Two hours later the patient was again tested positive for SARS-CoV-2 with a Ct value of 12.8 in the RT-PCR (Cepheid Xpert Xpress SARS-CoV-2 point-ofcare test, Sunnyvale, CA, USA). Another oropharyngeal swab was taken confirming the positive SARS-CoV-2 RT-PCR test result with a Ct value of 14.5 using a different platform (cobas 6800 SARS-CoV-2 test, Roche, Molecular Systems, Branchburg, NJ, USA).

Despite primary SARS-CoV-2 infection the patient this time required additional oxygen and had viral pneumonia on chest X-ray. Furthermore, the patient received low molecular weight heparin with enoxaparin 4000 I.E. subcutaneously once daily for prophylaxis of venous thromboembolism and paracetamol 1000 mg intravenously as antipyretic treatment. Antiviral treatment was not administered due to drug shortage of remdesivir in Upper Austria at this time. We did not give dexamethasone at admission because the patient was not critically ill, he had no laboratory findings of hyperinflammation and was in the early phase of viral infection. Over the next few days the patients' respiratory condition deteriorated continuously consistent with a severe course of COVID-19. Finally, the patient deceased 6 days after admission.

Taken this together a COVID-19 reinfection seems to be plausible in our patient 124 days after primary SARS-CoV-2 infection, although a recently published clinical meta-analysis including 15 single or cumulative case reports did not find any clinical reinfec-letter to the editor tion after a 70-day period following first infection [1] . These findings are supported by animal studies demonstrating protection against reinfection in rhesus macaques after primary exposure to SARS-CoV-2 [2, 3] . Nevertheless, the first and the second COVID-19 episode in our patient were characterized by clinical symptoms, typical laboratory findings including leukopenia and thrombocytopenia as well as repeated virological confirmation of SARS-CoV-2 infection, while he had no symptoms and he tested negative on several occasions in between. To KK-W et al. also reported a reinfection in a 33-year-old man 142 days after first infection. Whole genome sequencing confirmed that both COVID-19 episodes were caused by phylogenetically diverse SARS-CoV-2 strains, which supports our clinical observation of reinfection instead of persistent viral shedding [4] . Questions remain, for example, why this patient acquired a COVID-19 reinfection, while immunity against the virus is probable, at least in the short term, since SARS-CoV-2 reinfections are only reported occasionally despite the high COVID-19 prevalence worldwide. Explanations could be an infection with a different SARS-CoV-2 strain or an age-related impaired immune response. Unfortunately we were not able to perform a comparison of whole genome sequencing data due to missing sample material of the first episode of infection.

We want to draw attention to this emerging aspect in the COVID-19 pandemic since reinfections will certainly influence our future scientific, clinical, social and economic response to COVID-19 pandemic. It will raise considerable questions on innate and adaptive immune response, on herd immunity and on vaccine development.

Current meta-analysis does not support the possibility of COVID-19 reinfections

Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques

SARS-CoV-2 infection protects against rechallenge in rhesus macaques

COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing

The first case of documented Covid-19 reinfection in Israel

COVID-19 reinfection by a phylogenetically distinct SARS-CoV-2 variant, first confirmed event in South America

Is novel coronavirus 2019 reinfection possible? Interpreting dynamic SARS-CoV-2 test results through a case report

Genomic evidence for reinfection with SARS-CoV-2: a case study

Symptomatic SARS-CoV-2 reinfection by a phylogenetically distinct strain

Reinfection of SARS-CoV-2 in an immunocompromised patient: a case report

Reinfection with SARS-CoV-2 and failure of humoral immunity: a case report

A Case of Early Reinfection with SARS-CoV-2

Case report: recurrent clinicalsymptomsofCOVID-19inhealthcareprofessionals: a series of cases from Brazil